Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 190 | 2022 | 2184 | 31.200 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 147 | 2022 | 978 | 31.090 |
Why?
|
Protein Kinase Inhibitors | 82 | 2022 | 858 | 13.800 |
Why?
|
Receptor Protein-Tyrosine Kinases | 47 | 2022 | 268 | 11.880 |
Why?
|
Antineoplastic Agents | 74 | 2021 | 2071 | 10.960 |
Why?
|
Pyrazoles | 45 | 2021 | 390 | 8.580 |
Why?
|
Pyrimidines | 31 | 2022 | 402 | 8.220 |
Why?
|
Pyridines | 38 | 2021 | 483 | 7.810 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 39 | 2022 | 1397 | 6.860 |
Why?
|
Gene Rearrangement | 25 | 2019 | 167 | 6.300 |
Why?
|
Organophosphorus Compounds | 15 | 2022 | 78 | 6.290 |
Why?
|
ErbB Receptors | 47 | 2022 | 549 | 5.850 |
Why?
|
Brain Neoplasms | 27 | 2022 | 960 | 5.010 |
Why?
|
Protein-Tyrosine Kinases | 25 | 2022 | 450 | 4.740 |
Why?
|
Drug Resistance, Neoplasm | 31 | 2021 | 681 | 4.220 |
Why?
|
Proto-Oncogene Proteins c-met | 20 | 2022 | 68 | 4.180 |
Why?
|
Proto-Oncogene Proteins | 25 | 2022 | 716 | 3.410 |
Why?
|
Immunoconjugates | 6 | 2021 | 93 | 3.290 |
Why?
|
Neoplasms | 28 | 2021 | 2037 | 3.180 |
Why?
|
Carbazoles | 12 | 2022 | 90 | 3.180 |
Why?
|
Piperidines | 11 | 2022 | 176 | 2.890 |
Why?
|
Adenocarcinoma | 16 | 2017 | 804 | 2.770 |
Why?
|
Humans | 252 | 2022 | 113846 | 2.660 |
Why?
|
Small Cell Lung Carcinoma | 13 | 2022 | 80 | 2.590 |
Why?
|
Mutation | 48 | 2022 | 3447 | 2.560 |
Why?
|
Middle Aged | 128 | 2021 | 28753 | 2.560 |
Why?
|
Acrylamides | 12 | 2022 | 41 | 2.560 |
Why?
|
Clinical Trials as Topic | 17 | 2022 | 1009 | 2.290 |
Why?
|
Biomarkers, Tumor | 24 | 2021 | 1045 | 2.290 |
Why?
|
Molecular Targeted Therapy | 14 | 2022 | 380 | 2.250 |
Why?
|
Aged | 105 | 2021 | 20109 | 2.240 |
Why?
|
Thoracic Neoplasms | 3 | 2019 | 35 | 2.150 |
Why?
|
Antibodies, Monoclonal, Humanized | 18 | 2022 | 634 | 2.060 |
Why?
|
Oncogene Proteins, Fusion | 8 | 2021 | 202 | 1.960 |
Why?
|
In Situ Hybridization, Fluorescence | 15 | 2021 | 330 | 1.900 |
Why?
|
Male | 136 | 2021 | 60993 | 1.860 |
Why?
|
Quinazolines | 11 | 2017 | 244 | 1.830 |
Why?
|
Aged, 80 and over | 58 | 2021 | 6796 | 1.820 |
Why?
|
Antibodies, Monoclonal | 14 | 2021 | 1302 | 1.800 |
Why?
|
Female | 136 | 2021 | 63035 | 1.760 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 5 | 2013 | 39 | 1.750 |
Why?
|
Mesothelioma | 4 | 2018 | 35 | 1.690 |
Why?
|
Neoplasm Staging | 28 | 2021 | 1226 | 1.650 |
Why?
|
Erlotinib Hydrochloride | 12 | 2022 | 70 | 1.640 |
Why?
|
Lactams, Macrocyclic | 7 | 2021 | 61 | 1.620 |
Why?
|
Adult | 95 | 2021 | 31979 | 1.570 |
Why?
|
Central Nervous System | 4 | 2021 | 248 | 1.570 |
Why?
|
Radiosurgery | 10 | 2022 | 298 | 1.530 |
Why?
|
Disease-Free Survival | 26 | 2020 | 682 | 1.490 |
Why?
|
Gene Dosage | 4 | 2018 | 148 | 1.480 |
Why?
|
Survival Rate | 23 | 2021 | 1854 | 1.400 |
Why?
|
Maximum Tolerated Dose | 20 | 2021 | 187 | 1.370 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2021 | 52 | 1.350 |
Why?
|
Imidazoles | 4 | 2018 | 259 | 1.290 |
Why?
|
Lung Diseases, Interstitial | 4 | 2020 | 407 | 1.280 |
Why?
|
Aniline Compounds | 8 | 2022 | 65 | 1.280 |
Why?
|
Piperazines | 3 | 2019 | 325 | 1.260 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 12 | 2019 | 241 | 1.240 |
Why?
|
Prognosis | 27 | 2022 | 3544 | 1.220 |
Why?
|
Cell Cycle | 6 | 2012 | 603 | 1.150 |
Why?
|
Oncogenes | 4 | 2019 | 109 | 1.150 |
Why?
|
Treatment Outcome | 41 | 2022 | 9002 | 1.140 |
Why?
|
Receptor, ErbB-2 | 9 | 2020 | 321 | 1.140 |
Why?
|
Proto-Oncogene Proteins c-ret | 2 | 2021 | 25 | 1.090 |
Why?
|
Disease Progression | 17 | 2022 | 2489 | 1.090 |
Why?
|
B7-H1 Antigen | 4 | 2020 | 132 | 1.090 |
Why?
|
Trastuzumab | 2 | 2021 | 95 | 1.090 |
Why?
|
Follow-Up Studies | 25 | 2021 | 4906 | 1.070 |
Why?
|
Camptothecin | 4 | 2020 | 87 | 1.060 |
Why?
|
Pleural Neoplasms | 3 | 2018 | 23 | 1.050 |
Why?
|
Immunotherapy | 5 | 2021 | 462 | 1.040 |
Why?
|
Glomerular Filtration Rate | 3 | 2019 | 575 | 1.020 |
Why?
|
Neoplasm Metastasis | 12 | 2020 | 616 | 1.010 |
Why?
|
Neuregulin-1 | 2 | 2021 | 46 | 0.990 |
Why?
|
Retrospective Studies | 32 | 2022 | 11340 | 0.990 |
Why?
|
Apoptosis | 7 | 2013 | 2675 | 0.980 |
Why?
|
Pyridazines | 3 | 2019 | 57 | 0.970 |
Why?
|
Paclitaxel | 9 | 2020 | 194 | 0.960 |
Why?
|
Hypogonadism | 2 | 2013 | 74 | 0.960 |
Why?
|
Endpoint Determination | 5 | 2018 | 69 | 0.960 |
Why?
|
Glutamates | 6 | 2014 | 59 | 0.940 |
Why?
|
Medical Oncology | 3 | 2021 | 189 | 0.930 |
Why?
|
Exons | 8 | 2022 | 317 | 0.930 |
Why?
|
Guanine | 6 | 2014 | 87 | 0.920 |
Why?
|
Carboplatin | 11 | 2021 | 138 | 0.920 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 5 | 2021 | 13 | 0.910 |
Why?
|
Survival Analysis | 11 | 2021 | 1414 | 0.890 |
Why?
|
ras Proteins | 8 | 2014 | 155 | 0.870 |
Why?
|
Authorship | 1 | 2021 | 42 | 0.870 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 59 | 0.860 |
Why?
|
Patient Selection | 5 | 2019 | 694 | 0.850 |
Why?
|
Carcinoma, Renal Cell | 2 | 2013 | 167 | 0.850 |
Why?
|
Dose-Response Relationship, Drug | 13 | 2021 | 2229 | 0.830 |
Why?
|
Biomarkers | 8 | 2019 | 3501 | 0.830 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2019 | 154 | 0.820 |
Why?
|
Kidney | 2 | 2019 | 1211 | 0.790 |
Why?
|
Lactams | 7 | 2021 | 39 | 0.790 |
Why?
|
Testosterone | 2 | 2013 | 307 | 0.790 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 214 | 0.780 |
Why?
|
Aminopyridines | 7 | 2021 | 88 | 0.780 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 789 | 0.770 |
Why?
|
Gene Amplification | 9 | 2019 | 107 | 0.750 |
Why?
|
Kidney Neoplasms | 2 | 2013 | 325 | 0.740 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2018 | 205 | 0.730 |
Why?
|
Cyclin-Dependent Kinases | 2 | 2010 | 116 | 0.720 |
Why?
|
Thromboembolism | 1 | 2018 | 104 | 0.710 |
Why?
|
Healthcare Disparities | 2 | 2021 | 465 | 0.700 |
Why?
|
Young Adult | 22 | 2020 | 10971 | 0.690 |
Why?
|
Kaplan-Meier Estimate | 14 | 2020 | 872 | 0.680 |
Why?
|
Pyrazines | 2 | 2019 | 86 | 0.680 |
Why?
|
Drug Administration Schedule | 10 | 2017 | 825 | 0.680 |
Why?
|
Liver Neoplasms | 2 | 2019 | 454 | 0.670 |
Why?
|
Central Nervous System Neoplasms | 4 | 2022 | 124 | 0.670 |
Why?
|
Creatinine | 2 | 2019 | 461 | 0.660 |
Why?
|
Receptors, Fibroblast Growth Factor | 2 | 2016 | 62 | 0.630 |
Why?
|
Mouth Mucosa | 2 | 2006 | 96 | 0.620 |
Why?
|
Hair | 2 | 2006 | 69 | 0.610 |
Why?
|
Triazoles | 2 | 2013 | 144 | 0.580 |
Why?
|
Cranial Irradiation | 7 | 2022 | 73 | 0.580 |
Why?
|
Indoles | 6 | 2021 | 357 | 0.570 |
Why?
|
DNA Copy Number Variations | 5 | 2019 | 159 | 0.560 |
Why?
|
Nitrofurantoin | 1 | 2014 | 7 | 0.560 |
Why?
|
Pemetrexed | 6 | 2014 | 30 | 0.560 |
Why?
|
Anti-Infective Agents, Urinary | 1 | 2014 | 14 | 0.560 |
Why?
|
Cystitis | 1 | 2014 | 23 | 0.560 |
Why?
|
Cohort Studies | 13 | 2021 | 5011 | 0.540 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 20 | 0.540 |
Why?
|
Crown Ethers | 1 | 2013 | 4 | 0.540 |
Why?
|
Circulating Tumor DNA | 3 | 2018 | 18 | 0.530 |
Why?
|
Taxoids | 5 | 2016 | 94 | 0.530 |
Why?
|
Blood-Brain Barrier | 2 | 2016 | 105 | 0.520 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2019 | 557 | 0.510 |
Why?
|
RNA, Messenger | 3 | 2018 | 2857 | 0.500 |
Why?
|
Signal Transduction | 8 | 2014 | 4923 | 0.500 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2009 | 23 | 0.490 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 14 | 0.480 |
Why?
|
Organoplatinum Compounds | 3 | 2012 | 42 | 0.480 |
Why?
|
Receptor, IGF Type 1 | 1 | 2012 | 59 | 0.470 |
Why?
|
Cell-Free Nucleic Acids | 3 | 2022 | 23 | 0.470 |
Why?
|
Point Mutation | 1 | 2013 | 258 | 0.470 |
Why?
|
Androgens | 1 | 2013 | 156 | 0.460 |
Why?
|
Sulfonamides | 5 | 2020 | 450 | 0.460 |
Why?
|
Translocation, Genetic | 1 | 2012 | 120 | 0.460 |
Why?
|
Tissue Distribution | 5 | 2020 | 383 | 0.460 |
Why?
|
Carcinoma, Large Cell | 1 | 2011 | 16 | 0.450 |
Why?
|
Keratin-18 | 1 | 2010 | 12 | 0.430 |
Why?
|
Smoking | 2 | 2018 | 1632 | 0.430 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2011 | 219 | 0.430 |
Why?
|
Cell Proliferation | 8 | 2014 | 2404 | 0.420 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2016 | 19 | 0.420 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2009 | 280 | 0.420 |
Why?
|
Estrenes | 1 | 2010 | 17 | 0.420 |
Why?
|
Lymphatic Metastasis | 2 | 2009 | 302 | 0.410 |
Why?
|
Drug Therapy, Combination | 1 | 2013 | 1004 | 0.410 |
Why?
|
Antimitotic Agents | 1 | 2009 | 9 | 0.410 |
Why?
|
Benzamides | 2 | 2022 | 186 | 0.410 |
Why?
|
Receptors, Somatomedin | 1 | 2009 | 4 | 0.410 |
Why?
|
Estradiol | 2 | 2010 | 452 | 0.400 |
Why?
|
Catheter Ablation | 1 | 2012 | 316 | 0.390 |
Why?
|
Caspase 3 | 1 | 2010 | 256 | 0.390 |
Why?
|
Genetic Testing | 2 | 2015 | 382 | 0.380 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2001 | 192 | 0.380 |
Why?
|
Programmed Cell Death 1 Receptor | 3 | 2019 | 182 | 0.380 |
Why?
|
Lung | 4 | 2019 | 3637 | 0.380 |
Why?
|
Sulfones | 4 | 2021 | 102 | 0.370 |
Why?
|
Mitosis | 1 | 2009 | 193 | 0.370 |
Why?
|
Adolescent | 12 | 2020 | 18736 | 0.370 |
Why?
|
Lymph Node Excision | 1 | 2009 | 126 | 0.370 |
Why?
|
Oligonucleotides, Antisense | 1 | 2008 | 107 | 0.360 |
Why?
|
Genotype | 4 | 2021 | 2074 | 0.340 |
Why?
|
Chemoradiotherapy | 2 | 2019 | 199 | 0.340 |
Why?
|
Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2006 | 7 | 0.340 |
Why?
|
HIV | 1 | 2008 | 206 | 0.340 |
Why?
|
Administration, Oral | 8 | 2015 | 798 | 0.330 |
Why?
|
Quality of Life | 5 | 2021 | 2136 | 0.330 |
Why?
|
Cell Line, Tumor | 9 | 2019 | 2936 | 0.330 |
Why?
|
Immunohistochemistry | 5 | 2022 | 1831 | 0.330 |
Why?
|
Etoposide | 4 | 2021 | 166 | 0.330 |
Why?
|
Accidents | 1 | 2007 | 42 | 0.330 |
Why?
|
Quinazolinones | 3 | 2016 | 17 | 0.330 |
Why?
|
Ethics, Medical | 1 | 2006 | 86 | 0.320 |
Why?
|
Cell Adhesion Molecules | 2 | 2017 | 190 | 0.310 |
Why?
|
Pharmacology | 1 | 2005 | 9 | 0.310 |
Why?
|
Pharmacokinetics | 1 | 2005 | 36 | 0.310 |
Why?
|
Technology, Pharmaceutical | 1 | 2005 | 32 | 0.310 |
Why?
|
Antigens, Neoplasm | 2 | 2017 | 235 | 0.300 |
Why?
|
Cough | 2 | 2017 | 96 | 0.290 |
Why?
|
DNA, Neoplasm | 2 | 2019 | 171 | 0.290 |
Why?
|
Precision Medicine | 4 | 2019 | 315 | 0.290 |
Why?
|
Mortality | 1 | 2007 | 328 | 0.290 |
Why?
|
Registries | 4 | 2021 | 1824 | 0.280 |
Why?
|
Time Factors | 7 | 2021 | 7060 | 0.280 |
Why?
|
Immunoenzyme Techniques | 3 | 2014 | 230 | 0.270 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 87 | 0.270 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 537 | 0.270 |
Why?
|
RNA | 3 | 2019 | 776 | 0.270 |
Why?
|
Leukocytes, Mononuclear | 1 | 2006 | 502 | 0.270 |
Why?
|
Radiotherapy Dosage | 3 | 2017 | 252 | 0.260 |
Why?
|
Combined Modality Therapy | 5 | 2017 | 1243 | 0.250 |
Why?
|
Prospective Studies | 6 | 2022 | 6250 | 0.250 |
Why?
|
Tumor Burden | 3 | 2018 | 281 | 0.250 |
Why?
|
Pyrroles | 3 | 2012 | 199 | 0.240 |
Why?
|
Treatment Failure | 3 | 2014 | 329 | 0.240 |
Why?
|
DNA Mutational Analysis | 3 | 2019 | 420 | 0.240 |
Why?
|
Benzodiazepinones | 1 | 2021 | 18 | 0.230 |
Why?
|
Nails, Malformed | 1 | 2001 | 5 | 0.230 |
Why?
|
Indazoles | 1 | 2022 | 68 | 0.230 |
Why?
|
Lymphoma, Follicular | 1 | 2021 | 38 | 0.230 |
Why?
|
Breast Neoplasms | 3 | 2020 | 1909 | 0.220 |
Why?
|
Fatigue | 5 | 2015 | 293 | 0.220 |
Why?
|
Carcinoma, Small Cell | 1 | 2001 | 175 | 0.220 |
Why?
|
Recurrence | 3 | 2018 | 967 | 0.220 |
Why?
|
Research Design | 5 | 2016 | 913 | 0.220 |
Why?
|
Epidermal Cyst | 1 | 2000 | 12 | 0.220 |
Why?
|
Bevacizumab | 2 | 2019 | 124 | 0.210 |
Why?
|
Policy | 1 | 2021 | 70 | 0.210 |
Why?
|
Biopsy | 3 | 2013 | 1065 | 0.210 |
Why?
|
Skin | 1 | 2005 | 702 | 0.210 |
Why?
|
Retreatment | 2 | 2017 | 66 | 0.210 |
Why?
|
Meningeal Neoplasms | 1 | 2021 | 80 | 0.210 |
Why?
|
Radiodermatitis | 1 | 2000 | 7 | 0.210 |
Why?
|
Neovascularization, Pathologic | 3 | 2012 | 291 | 0.210 |
Why?
|
Quality-Adjusted Life Years | 2 | 2021 | 114 | 0.210 |
Why?
|
Deglutition Disorders | 1 | 2001 | 122 | 0.210 |
Why?
|
Standard of Care | 1 | 2020 | 88 | 0.200 |
Why?
|
Oncogene Protein p21(ras) | 1 | 2019 | 26 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 234 | 0.200 |
Why?
|
Suicide | 1 | 2007 | 521 | 0.200 |
Why?
|
Lymphoma, B-Cell | 1 | 2000 | 95 | 0.200 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 83 | 0.200 |
Why?
|
Consolidation Chemotherapy | 1 | 2019 | 13 | 0.200 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 271 | 0.200 |
Why?
|
Organs at Risk | 1 | 2019 | 32 | 0.200 |
Why?
|
Cisplatin | 4 | 2014 | 284 | 0.200 |
Why?
|
Aminoquinolines | 1 | 2019 | 18 | 0.200 |
Why?
|
Diarrhea | 2 | 2017 | 178 | 0.200 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2019 | 13 | 0.190 |
Why?
|
Positron-Emission Tomography | 4 | 2014 | 301 | 0.190 |
Why?
|
Animals | 15 | 2019 | 35394 | 0.190 |
Why?
|
Oncogene Proteins | 1 | 2019 | 67 | 0.190 |
Why?
|
Radiotherapy, Conformal | 2 | 2017 | 69 | 0.190 |
Why?
|
Gene Fusion | 1 | 2018 | 21 | 0.190 |
Why?
|
Antinematodal Agents | 1 | 2018 | 6 | 0.190 |
Why?
|
Incidence | 3 | 2020 | 2470 | 0.190 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2012 | 517 | 0.190 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 56 | 0.190 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 76 | 0.190 |
Why?
|
Drug Approval | 1 | 2018 | 72 | 0.180 |
Why?
|
Gold | 1 | 2019 | 105 | 0.180 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2018 | 218 | 0.180 |
Why?
|
Radiotherapy | 3 | 2016 | 203 | 0.180 |
Why?
|
Hospitalization | 1 | 2007 | 1678 | 0.180 |
Why?
|
Multivariate Analysis | 2 | 2019 | 1599 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2022 | 325 | 0.170 |
Why?
|
Drowning | 1 | 2017 | 11 | 0.170 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 320 | 0.170 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 1141 | 0.170 |
Why?
|
Thymus Neoplasms | 1 | 2017 | 21 | 0.170 |
Why?
|
Thymoma | 1 | 2017 | 32 | 0.170 |
Why?
|
Scotland | 2 | 2007 | 14 | 0.170 |
Why?
|
Immunity, Cellular | 1 | 2019 | 307 | 0.170 |
Why?
|
Receptors, Growth Factor | 3 | 2011 | 57 | 0.170 |
Why?
|
Benzimidazoles | 3 | 2018 | 147 | 0.170 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 1432 | 0.170 |
Why?
|
Nausea | 1 | 2017 | 116 | 0.160 |
Why?
|
Head and Neck Neoplasms | 1 | 2021 | 400 | 0.160 |
Why?
|
Headache | 1 | 2017 | 114 | 0.160 |
Why?
|
Pleural Effusion, Malignant | 1 | 2016 | 16 | 0.160 |
Why?
|
Decision Trees | 1 | 2016 | 83 | 0.160 |
Why?
|
Centrosome | 1 | 2016 | 67 | 0.160 |
Why?
|
Adjuvants, Immunologic | 1 | 2017 | 234 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2016 | 58 | 0.150 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2014 | 366 | 0.150 |
Why?
|
Peritoneal Neoplasms | 1 | 2016 | 59 | 0.150 |
Why?
|
Markov Chains | 1 | 2016 | 127 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 1136 | 0.150 |
Why?
|
Postoperative Care | 1 | 2017 | 233 | 0.150 |
Why?
|
Pneumonia | 1 | 2020 | 558 | 0.150 |
Why?
|
Chronic Disease | 2 | 2014 | 1681 | 0.150 |
Why?
|
Neutropenia | 4 | 2019 | 133 | 0.140 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2022 | 195 | 0.140 |
Why?
|
Risk Assessment | 5 | 2015 | 3147 | 0.140 |
Why?
|
Drug Interactions | 2 | 2013 | 423 | 0.140 |
Why?
|
Cryptogenic Organizing Pneumonia | 1 | 2014 | 18 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 5 | 2018 | 3049 | 0.140 |
Why?
|
Structure-Activity Relationship | 2 | 2018 | 576 | 0.140 |
Why?
|
Australia | 2 | 2012 | 221 | 0.140 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2014 | 34 | 0.140 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 1123 | 0.140 |
Why?
|
HIV Infections | 1 | 2008 | 2487 | 0.140 |
Why?
|
Skin Neoplasms | 1 | 2000 | 737 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2013 | 86 | 0.130 |
Why?
|
Reproducibility of Results | 3 | 2006 | 2905 | 0.130 |
Why?
|
Threonine | 1 | 2013 | 50 | 0.130 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2013 | 54 | 0.130 |
Why?
|
Sequence Analysis, DNA | 2 | 2014 | 798 | 0.130 |
Why?
|
GTP Phosphohydrolases | 1 | 2013 | 63 | 0.130 |
Why?
|
Sodium-Phosphate Cotransporter Proteins, Type IIb | 1 | 2012 | 13 | 0.130 |
Why?
|
Dyspnea | 1 | 2014 | 186 | 0.120 |
Why?
|
Focal Adhesion Kinase 2 | 1 | 2012 | 4 | 0.120 |
Why?
|
Disease Management | 2 | 2020 | 606 | 0.120 |
Why?
|
Methionine | 1 | 2013 | 155 | 0.120 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2013 | 74 | 0.120 |
Why?
|
Luteinizing Hormone | 1 | 2013 | 188 | 0.120 |
Why?
|
Periodicals as Topic | 1 | 2016 | 264 | 0.120 |
Why?
|
Heterozygote | 1 | 2013 | 270 | 0.120 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2012 | 29 | 0.120 |
Why?
|
Serum Albumin | 1 | 2013 | 161 | 0.120 |
Why?
|
Thiophenes | 1 | 2013 | 107 | 0.120 |
Why?
|
Biomedical Research | 2 | 2010 | 609 | 0.120 |
Why?
|
Follicle Stimulating Hormone | 1 | 2013 | 220 | 0.120 |
Why?
|
Quinolines | 1 | 2013 | 130 | 0.120 |
Why?
|
Glioma | 1 | 2015 | 274 | 0.120 |
Why?
|
Niacinamide | 1 | 2012 | 71 | 0.120 |
Why?
|
Genes, ras | 1 | 2012 | 98 | 0.120 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2012 | 92 | 0.120 |
Why?
|
Biological Transport | 1 | 2013 | 435 | 0.120 |
Why?
|
Hydroxamic Acids | 1 | 2012 | 87 | 0.120 |
Why?
|
Fluorouracil | 2 | 2012 | 139 | 0.120 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 30 | 0.110 |
Why?
|
Radiation Pneumonitis | 1 | 2011 | 29 | 0.110 |
Why?
|
Induction Chemotherapy | 1 | 2011 | 53 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 4 | 2015 | 2380 | 0.110 |
Why?
|
Vimentin | 1 | 2011 | 60 | 0.110 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 676 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2015 | 336 | 0.110 |
Why?
|
Phytotherapy | 1 | 2011 | 69 | 0.110 |
Why?
|
Genes, bcl-2 | 1 | 2011 | 21 | 0.110 |
Why?
|
Area Under Curve | 2 | 2012 | 328 | 0.110 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2019 | 446 | 0.110 |
Why?
|
Blotting, Western | 2 | 2014 | 1316 | 0.110 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 14 | 0.110 |
Why?
|
Heptanoic Acids | 1 | 2011 | 68 | 0.110 |
Why?
|
Deoxycytidine | 2 | 2011 | 146 | 0.110 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 222 | 0.110 |
Why?
|
Amino Acid Chloromethyl Ketones | 1 | 2010 | 32 | 0.110 |
Why?
|
Models, Molecular | 2 | 2018 | 1604 | 0.110 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2010 | 60 | 0.110 |
Why?
|
In Situ Nick-End Labeling | 1 | 2010 | 138 | 0.110 |
Why?
|
Alcohol Drinking | 1 | 2017 | 721 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2012 | 201 | 0.100 |
Why?
|
Caspase Inhibitors | 1 | 2010 | 96 | 0.100 |
Why?
|
Cadherins | 1 | 2011 | 191 | 0.100 |
Why?
|
Cannabinoids | 1 | 2011 | 114 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 27 | 0.100 |
Why?
|
Rats | 2 | 2010 | 6387 | 0.100 |
Why?
|
Immunoblotting | 1 | 2010 | 375 | 0.100 |
Why?
|
Cognition | 2 | 2016 | 964 | 0.100 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2011 | 169 | 0.100 |
Why?
|
Pharmacogenetics | 1 | 2010 | 170 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 2424 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 788 | 0.100 |
Why?
|
Demography | 1 | 2010 | 294 | 0.100 |
Why?
|
Protein Structure, Tertiary | 1 | 2012 | 906 | 0.090 |
Why?
|
Weight Loss | 1 | 2014 | 694 | 0.090 |
Why?
|
Dogs | 1 | 2010 | 472 | 0.090 |
Why?
|
Floxuridine | 1 | 2008 | 8 | 0.090 |
Why?
|
Protein Kinase C beta | 1 | 2008 | 29 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2009 | 127 | 0.090 |
Why?
|
United States | 5 | 2022 | 12329 | 0.090 |
Why?
|
Capecitabine | 1 | 2008 | 43 | 0.090 |
Why?
|
Marijuana Smoking | 1 | 2011 | 226 | 0.090 |
Why?
|
Species Specificity | 1 | 2010 | 649 | 0.090 |
Why?
|
RNA Interference | 1 | 2010 | 515 | 0.090 |
Why?
|
Double-Blind Method | 2 | 2016 | 1673 | 0.090 |
Why?
|
Medical Records | 1 | 2009 | 182 | 0.090 |
Why?
|
Risk Factors | 4 | 2019 | 9050 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 1 | 2010 | 224 | 0.090 |
Why?
|
Clinical Decision-Making | 2 | 2022 | 274 | 0.090 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 1100 | 0.090 |
Why?
|
Health Services Accessibility | 1 | 2014 | 777 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 909 | 0.090 |
Why?
|
Everolimus | 2 | 2020 | 57 | 0.090 |
Why?
|
Salvage Therapy | 2 | 2019 | 137 | 0.090 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 68 | 0.080 |
Why?
|
Electronic Health Records | 1 | 2013 | 670 | 0.080 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 1529 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2008 | 128 | 0.080 |
Why?
|
Retinoblastoma Protein | 1 | 2006 | 54 | 0.080 |
Why?
|
Scalp | 1 | 2006 | 26 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 1930 | 0.080 |
Why?
|
Colorectal Neoplasms | 1 | 2013 | 584 | 0.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 104 | 0.080 |
Why?
|
Placebos | 1 | 2006 | 216 | 0.080 |
Why?
|
Cannabis | 1 | 2011 | 292 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 465 | 0.080 |
Why?
|
Membrane Proteins | 1 | 2013 | 1098 | 0.080 |
Why?
|
Brain | 1 | 2018 | 2686 | 0.080 |
Why?
|
Cetuximab | 2 | 2017 | 95 | 0.080 |
Why?
|
Protein Kinase C | 1 | 2008 | 354 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 447 | 0.080 |
Why?
|
Receptors, Estrogen | 1 | 2008 | 399 | 0.080 |
Why?
|
Hair Follicle | 1 | 2005 | 55 | 0.070 |
Why?
|
Melanocytes | 1 | 2005 | 67 | 0.070 |
Why?
|
Cell Line | 1 | 2012 | 3016 | 0.070 |
Why?
|
Cross-Over Studies | 1 | 2006 | 484 | 0.070 |
Why?
|
Reference Values | 1 | 2006 | 877 | 0.070 |
Why?
|
Tumor Cells, Cultured | 2 | 2019 | 1041 | 0.070 |
Why?
|
Monocytes | 1 | 2008 | 517 | 0.070 |
Why?
|
Safety | 1 | 2006 | 319 | 0.070 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2014 | 74 | 0.070 |
Why?
|
Specimen Handling | 1 | 2005 | 176 | 0.070 |
Why?
|
Risk | 1 | 2007 | 943 | 0.070 |
Why?
|
Models, Biological | 1 | 2012 | 1845 | 0.070 |
Why?
|
Delivery of Health Care | 1 | 2010 | 695 | 0.070 |
Why?
|
Phosphorylation | 1 | 2008 | 1742 | 0.060 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2014 | 72 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2014 | 352 | 0.060 |
Why?
|
Pharyngeal Diseases | 1 | 2001 | 18 | 0.060 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2021 | 27 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 1210 | 0.060 |
Why?
|
Esophageal Diseases | 1 | 2001 | 28 | 0.060 |
Why?
|
Opportunistic Infections | 1 | 2001 | 53 | 0.060 |
Why?
|
Asia | 1 | 2021 | 56 | 0.060 |
Why?
|
Mediastinal Neoplasms | 1 | 2001 | 41 | 0.060 |
Why?
|
Sex Characteristics | 1 | 2006 | 662 | 0.060 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2001 | 56 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2022 | 179 | 0.060 |
Why?
|
Mutagenesis, Insertional | 1 | 2021 | 63 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2001 | 75 | 0.060 |
Why?
|
Brain Stem Neoplasms | 1 | 2001 | 79 | 0.050 |
Why?
|
Surveys and Questionnaires | 1 | 2013 | 4625 | 0.050 |
Why?
|
Carbon Monoxide | 1 | 2020 | 72 | 0.050 |
Why?
|
Europe | 1 | 2021 | 351 | 0.050 |
Why?
|
Thrombocytopenia | 2 | 2012 | 184 | 0.050 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2019 | 29 | 0.050 |
Why?
|
Ipilimumab | 1 | 2019 | 33 | 0.050 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 143 | 0.050 |
Why?
|
Lymphopenia | 1 | 2019 | 57 | 0.050 |
Why?
|
Mice | 4 | 2019 | 15641 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2020 | 191 | 0.050 |
Why?
|
Age Factors | 1 | 2007 | 3330 | 0.050 |
Why?
|
Leukocyte Count | 1 | 2019 | 325 | 0.050 |
Why?
|
Organoids | 1 | 2019 | 60 | 0.050 |
Why?
|
Liquid Biopsy | 1 | 2018 | 6 | 0.050 |
Why?
|
Genes, erbB-1 | 1 | 2018 | 22 | 0.050 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 112 | 0.050 |
Why?
|
Radiation Dosage | 1 | 2019 | 144 | 0.040 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2019 | 132 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2020 | 739 | 0.040 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2017 | 14 | 0.040 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2017 | 14 | 0.040 |
Why?
|
Immune System | 1 | 2019 | 198 | 0.040 |
Why?
|
Practice Patterns, Physicians' | 1 | 2006 | 1214 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 74 | 0.040 |
Why?
|
Lymphocytes | 1 | 2019 | 392 | 0.040 |
Why?
|
Exanthema | 1 | 2017 | 63 | 0.040 |
Why?
|
Exosomes | 1 | 2018 | 80 | 0.040 |
Why?
|
Hyperphosphatemia | 1 | 2016 | 12 | 0.040 |
Why?
|
Palliative Care | 2 | 2014 | 631 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2016 | 61 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 1326 | 0.040 |
Why?
|
Myalgia | 1 | 2015 | 16 | 0.040 |
Why?
|
Creatine Kinase | 1 | 2015 | 90 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2015 | 38 | 0.040 |
Why?
|
Drug Therapy | 1 | 2016 | 82 | 0.040 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 369 | 0.040 |
Why?
|
Aspartate Aminotransferases | 1 | 2015 | 102 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2015 | 151 | 0.040 |
Why?
|
Edema | 1 | 2015 | 116 | 0.040 |
Why?
|
Constipation | 1 | 2015 | 71 | 0.040 |
Why?
|
Heart | 1 | 2019 | 685 | 0.040 |
Why?
|
Gonanes | 1 | 2014 | 28 | 0.040 |
Why?
|
Proto-Oncogenes | 1 | 2014 | 31 | 0.040 |
Why?
|
Texas | 1 | 2014 | 185 | 0.030 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2014 | 38 | 0.030 |
Why?
|
United Kingdom | 1 | 2014 | 246 | 0.030 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 164 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2013 | 162 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2014 | 309 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2014 | 138 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 88 | 0.030 |
Why?
|
Vision Disorders | 1 | 2014 | 122 | 0.030 |
Why?
|
Computational Biology | 1 | 2018 | 674 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 2014 | 177 | 0.030 |
Why?
|
Syndecan-4 | 1 | 2012 | 9 | 0.030 |
Why?
|
Neutrophils | 1 | 2019 | 1324 | 0.030 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 44 | 0.030 |
Why?
|
Sirolimus | 1 | 2013 | 182 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2013 | 89 | 0.030 |
Why?
|
Leucovorin | 1 | 2012 | 42 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2014 | 286 | 0.030 |
Why?
|
Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 19 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2012 | 140 | 0.030 |
Why?
|
Mice, SCID | 1 | 2013 | 363 | 0.030 |
Why?
|
Midazolam | 1 | 2012 | 52 | 0.030 |
Why?
|
Pyridones | 1 | 2013 | 107 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 442 | 0.030 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2012 | 60 | 0.030 |
Why?
|
Biological Availability | 1 | 2011 | 159 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2012 | 91 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 1206 | 0.030 |
Why?
|
Gene Frequency | 1 | 2013 | 572 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 130 | 0.030 |
Why?
|
Receptor, ErbB-4 | 1 | 2011 | 19 | 0.030 |
Why?
|
Mice, Nude | 1 | 2013 | 700 | 0.030 |
Why?
|
Canada | 1 | 2012 | 336 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2013 | 324 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2013 | 415 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 382 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 207 | 0.030 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2010 | 29 | 0.030 |
Why?
|
Capsules | 1 | 2010 | 41 | 0.030 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 107 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2011 | 154 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 95 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2014 | 1211 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 69 | 0.030 |
Why?
|
Cell Survival | 1 | 2013 | 1188 | 0.030 |
Why?
|
Alopecia | 1 | 2009 | 31 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 213 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2010 | 412 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2010 | 166 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 5249 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2008 | 80 | 0.020 |
Why?
|
Anemia | 1 | 2009 | 166 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2008 | 405 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 945 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 728 | 0.020 |
Why?
|
California | 1 | 2008 | 369 | 0.020 |
Why?
|
DNA Repair | 1 | 2008 | 187 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2010 | 574 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2010 | 304 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2010 | 331 | 0.020 |
Why?
|
Pain | 1 | 2011 | 745 | 0.020 |
Why?
|
DNA Damage | 1 | 2008 | 373 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 1141 | 0.020 |
Why?
|
Colorado | 1 | 2014 | 4581 | 0.020 |
Why?
|
MicroRNAs | 1 | 2010 | 626 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 2025 | 0.020 |
Why?
|